Nextleaf Solutions Reports Record Revenue $3.4 Million in Second Quarter 2024 Financial Results
Nextleaf Solutions Reports Record Revenue $3.4 Million in Second Quarter 2024 Financial Results
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2024) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf", "OILS", or the "Company"), a leading life science firm and licensed cannabis processor, is pleased to release its financial results for their second quarter ended March 31st, 2024. The Company achieved sequential revenue growth, a record $3.4 million net revenue, and an adjusted EBITDA[1] of $232,682.
不列顛哥倫比亞省溫哥華--(Newsfile Corp.-2024 年 5 月 29 日)- Nextleaf Solutions Ltd.(CSE:OILS)(場外交易代碼:OILFF)(FSE:L0MA)(“Nextleaf”、“OILS” 或 “公司”)是一家領先的生命科學公司和持牌大麻加工商,很高興公佈截至3月31日的第二季度財務業績st,2024。公司實現收入連續增長,淨收入達到創紀錄的340萬美元,調整後的息稅折舊攤銷前利潤[1] 爲232,682美元。
Highlights
亮點
- Achieved gross margins of 28% in Q2 FY2024, up from 20% in Q2 FY2023.
- Net revenue grew by 7% to $3.4 million compared to the previous quarter and by 57% compared to Q2 FY2023. Revenue growth attributed to steady product innovation with 9 product launches in this quarter.
- The reported Loss of $1.01M for the quarter was primarily attributed to a non-cash charge related to a Share-Based Compensation expense.
- For the six months ended Q2-2024, the Company achieved an Adjusted EBITDA[2] of $554,638, marking a significant improvement compared to a loss of $201,951 in the same period of the previous year.
- Further strengthened its balance sheet by reducing its CRA liability by $740,000.
- Strong performance across all cannabis softgel and THC Oil SKUs with 21% and 32% growth rates respectively.
- Successful first shipment of white label vapes for a new commercial partner.
- The Company issued shares and stock options as part of an employee retention and incentivization initiative, with employees voluntarily electing to receive share payments instead of cash - demonstrating strong corporate alignment and dedication.
- New category launch of Glacial Gold MAX THC Infused Pre-rolls into major markets including BC, Alberta, and Ontario.
- 9 new product launches this quarter:
- Glacial Gold Balanced 10:10 Softgels 100-pack
- Glacial Gold CBD 50 Softgels 100-pack
- Glacial Gold MAX THC Grape Escape Double D Infused Pre-rolls 3x0.7g
- Glacial Gold MAX THC Cherry K.O. Double D Infused Pre-rolls 3x0.7g
- Glacial Gold MAX THC Blueberry Dream Hybrid Vape 1.2g
- Glacial Gold MAX THC Kush Mintz Hybrid Vape 1.2g
- Glacial Gold HIGH THC Berry Blotto Vape 1g
- High Plains 1000mg Indica THC Oil Drops 35ml
- High Plains 2000mg Balanced Oil Drops 35ml
- FY2024 第二季度實現了 28% 的毛利率,高於 FY2023 第二季度的20%。
- 與上一季度相比,淨收入增長了7%,達到340萬美元,與 FY2023 第二季度相比增長了57%。收入增長歸因於穩定的產品創新,本季度推出了9種產品。
- 本季度報告的101萬美元虧損主要歸因於與股份薪酬支出相關的非現金費用。
- 在截至 Q2-2024 的六個月中,公司實現了調整後的息稅折舊攤銷前利潤[2] 爲554,638美元,與去年同期的虧損201,951美元相比有了顯著改善。
- 通過將其CRA負債減少740,000美元,進一步加強了其資產負債表。
- 所有大麻軟膠囊和四氫大麻酚油SKU均表現強勁,增長率分別爲21%和32%。
- 成功爲新的商業合作伙伴首次出貨白標電子煙。
- 作爲員工留用和激勵計劃的一部分,公司發行了股票和股票期權,員工自願選擇接受股票支付而不是現金,這表明了企業強烈的團結和奉獻精神。
- 向不列顛哥倫比亞省、艾伯塔省和安大略省等主要市場推出新品類的Glacial Gold MAX 四氫大麻酚注入預售卷。
- 本季度發佈了9款新產品:
- Glacial Gold Balanced 10:10 軟膠囊 100 支裝
- Glacial Gold CBD 50 粒軟膠囊 100 包
- Glacial Gold MAX 四氫大麻酚 Grape Escape Double D 注入預卷 3x0.7g
- Glacial Gold MAX THC Cherry K.O. Double D 注入預卷 3x0.7g
- Glacial Gold MAX 四氫大麻酚藍莓夢幻混合電子煙 1.2g
- Glacial Gold MAX THC Kush Mintz Hybrid Vape 1.2g
- Glacial Gold HIGH THC Berry Blotto Vape 1g
- High Plains 1000mg 印度四氫大麻酚油滴劑 35ml
- High Plains 2000mg 平衡油滴劑 35ml
Adjusted EBITDA[3]
調整後 EBITDA[3]
Six months ended | March 31, 2024 $ |
March 31, 2023 $ |
|||||
Loss and comprehensive loss | (879,052) | (584,191) | |||||
Non-operating Items: | |||||||
Depreciation & Amortization | 349,906 | 366,714 | |||||
Interests | 29,496 | 15,526 | |||||
Taxes | |||||||
EBITDA | (499,650) | (201,951) | |||||
Non-operating Items: | |||||||
Share-based compensation expense | 1,054,288 | - | |||||
Adjusted EBITDA | 554,638 | (201,951) | |||||
Three months ended | March 31, 2024 $ |
March 31, 2023 $ |
|||||
Loss and comprehensive loss | (1,011,873) | (25,168) | |||||
Non-operating Items: | |||||||
Depreciation & Amortization | 175,780 | 182,762 | |||||
Interests | 14,487 | (10,038) | |||||
Taxes | |||||||
EBITDA | (821,606) | 147,556 | |||||
Non-operating Items: | |||||||
Share-based compensation expense | 1,054,288 | - | |||||
Adjusted EBITDA | 232,682 | 147,556 |
六個月已結束 | 3月31日 2024 $ |
3月31日 2023 $ |
|||||
損失和綜合損失 | (879,052) | (584,191) | |||||
非經營項目: | |||||||
折舊與攤銷 | 349,906 | 366,714 | |||||
興趣愛好 | 29,496 | 15,526 | |||||
稅收 | |||||||
EBITDA | (499,650) | (201,951) | |||||
非經營項目: | |||||||
基於股份的薪酬支出 | 1,054,288 | - | |||||
調整後 EBITDA | 554,638 | (201,951) | |||||
三個月結束了 | 3月31日 2024 $ |
3月31日 2023 $ |
|||||
損失和綜合損失 | (1,011,873) | (25,168) | |||||
非經營項目: | |||||||
折舊與攤銷 | 175,780 | 182,762 | |||||
興趣愛好 | 14,487 | (10,038) | |||||
稅收 | |||||||
EBITDA | (821,606) | 147,556 | |||||
非經營項目: | |||||||
基於股份的薪酬支出 | 1,054,288 | - | |||||
調整後 EBITDA | 232,682 | 147,556 |
"We have been diligently focused on executing our commercialization roadmap and product pipeline throughout this past quarter. We've made strategic investments into building up our inventory to strengthen our position, boost commercialization efforts, and expand territory sales," shares Emma Andrews, Interim CEO. "We're excited about the growth we're seeing across our key categories, and we are motivated to continue setting the standard for unparalleled value."
“在過去的一個季度中,我們一直努力地專注於執行我們的商業化路線圖和產品管道。我們已經進行了戰略投資,以增加庫存,以鞏固我們的地位,促進商業化努力並擴大區域銷售。” 臨時首席執行官艾瑪·安德魯斯分享道。“我們對關鍵類別的增長感到興奮,我們有動力繼續爲無與倫比的價值設定標準。”
2024 Outlook
2024 年展望
The Company will prioritize the following strategic initiatives throughout the third and fourth quarters FY2024:
在 FY2024 的第三和第四季度,公司將優先考慮以下戰略舉措:
- Brand Building & Marketing: Implementing strategic marketing campaigns and activations to elevate brand awareness and recognition among Canadian consumers.
- Increasing Points of Distribution: Expanding the number of distribution points within core markets and strengthening retailer relationships.
- Commercialization & Product Development: 12 new SKUs nationally.
- Inventory Building: Continued investment into building up inventory, including biomass procurement, through to finished products.
- Operational Efficiency: Improving operational efficiency through the integration of an ERP system.
- Commercial Partners Program Expansion: achieved through ingredient supply, white labeling, contract manufacturing, and toll processing activities for new and recurring clients.
- 品牌建設與營銷:實施戰略營銷活動和活動,以提高加拿大消費者的品牌知名度和認可度。
- 增加分銷點:擴大核心市場內的分銷點數量並加強零售商關係。
- 商業化和產品開發:全國有12個新的SKU。
- 庫存積累:持續投資積累庫存,包括生物質採購,直至成品。
- 運營效率:通過集成 ERP 系統提高運營效率。
- 商業合作伙伴計劃擴展:通過原料供應、白色標籤、合同製造以及針對新老客戶的收費處理活動來實現。
About Nextleaf Solutions Ltd.
關於 Nextleaf 解決方案有限公司
Nextleaf is an innovative cannabis processor with a portfolio of federally regulated emerging consumer brands, market validated cannabis derivative products, and high-potency bulk ingredients. Nextleaf's multi-patented, highly automated, closed loop extraction, and distillation technology sets the global standard for processing cannabis at scale.
Nextleaf是一家創新的大麻加工商,擁有一系列受聯邦監管的新興消費品牌、經過市場驗證的大麻衍生產品和高效散裝成分。Nextleaf 的多項專利、高度自動化、閉環提取和蒸餾技術爲大規模加工大麻設定了全球標準。
The Company currently manufactures over 80 different products, across 4 categories for white label clients and house brands. Formulated products and bulk ingredients are sold domestically to B2B partners and exported to applicable international jurisdictions. With coast-to-coast distribution, Nextleaf brands are sold through both medical and recreational channels and includes acclaimed legacy-era brand Glacial Gold, and High Plains Cannabis.
該公司目前爲白標客戶和自有品牌生產80多種不同的產品,涵蓋4個類別。配方產品和散裝原料在國內銷售給B2B合作伙伴,並出口到適用的國際司法管轄區。通過從海岸到海岸的分銷,Nextleaf品牌通過醫療和娛樂渠道銷售,其中包括備受讚譽的傳統時代品牌Glacial Gold和High Plains Cannabis。
Nextleaf's commitment to constant innovation, and speed-to-market advantage is guided by their team's unique depth of industry experience, complimented by their Health Canada Research License allowing for unique sensory evaluation of cannabis via human trials, and rapid prototyping. The Company has been issued 19 U.S. patents, and 75+ patents globally, on cannabinoid processing including extraction, distillation, and acetylation.
Nextleaf對持續創新和加快上市優勢的承諾以其團隊獨特的行業經驗深度爲指導,並輔之以加拿大衛生部研究許可證,允許通過人體試驗和快速原型設計對大麻進行獨特的感官評估。該公司已獲得19項美國專利,全球超過75項專利,涉及大麻素加工,包括提取、蒸餾和乙酰化。
On behalf of the Board of Directors of the Company,
Emma Andrews, Interim CEO
我代表本公司董事會,
艾瑪·安德魯斯,臨時首席執行官
Contact: investors@nextleafsolutions.com
聯繫人:investors@nextleafsolutions.com
Follow Nextleaf Solutions on LinkedIn
Learn More:
在領英上關注 Nextleaf 解決方案
了解更多:
Nextleaf trades as OILS on the Canadian Securities Exchange, OILFF on the OTCQB Market in the United States, and L0MA on the Frankfurt Stock Exchange.
Nextleaf在加拿大證券交易所以OILS的名義交易,在美國的OTCQB市場上以OILFF的身份交易,在法蘭克福證券交易所以L0MA的身份交易。
Disclaimers and Disclosure Statements:
免責聲明和披露聲明:
Certain statements contained in this press release constitute "forward-looking statements" within the meaning of applicable securities laws. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding the Company's anticipated delivery of its products to provincial markets across Canada and those regarding the Company's strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words "believe", "expect", "aim", "intend", "plan", "continue", "will", "may", "would", "anticipate", "estimate", "forecast", "predict", "project", "seek", "should" or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company's expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. Additional factors that could cause actual results, performance or achievements to differ materially include, but are not limited to the risk factors discussed in the Company's MD&A for the most recent fiscal period. Management provides forward-looking statements because it believes they provide useful information to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Consequently, all of the forward-looking statements made in this press release are qualified by these cautionary statements and other cautionary statements or factors contained herein, and there can be no assurance that the actual results or developments will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. The Canadian Securities Exchange has not reviewed or approved the contents of this press release.
本新聞稿中包含的某些陳述構成適用證券法所指的 “前瞻性陳述”。除本新聞稿中包含的歷史事實陳述以外的所有聲明,包括但不限於關於公司預期向加拿大各省市場交付產品的聲明,以及與公司戰略、計劃、目標、目標和目標有關的聲明,以及任何前面加上、後面或包含 “相信”、“期望”、“目標”、“打算”、“計劃”、“繼續”、“將”、“可能” 等字樣的聲明、“將”、“預測”、“估計”、“預測”、“預測”、“項目”、“尋求”、“應該” 或類似的表述或否定的,是前瞻性陳述。這些陳述不是歷史事實,而僅代表公司對未來事件的預期、估計和預測。這些陳述不能保證未來的表現,涉及難以預測的假設、風險和不確定性。因此,實際結果可能與此類前瞻性陳述中表達、暗示或預測的結果存在重大差異。可能導致實際業績、業績或成就出現重大差異的其他因素包括但不限於公司最近財年管理與分析中討論的風險因素。管理層之所以提供前瞻性陳述,是因爲它認爲這些陳述爲投資者在考慮投資目標時提供了有用的信息,並提醒投資者不要過分依賴前瞻性信息。因此,本新聞稿中發表的所有前瞻性陳述均受這些警示性陳述以及其中包含的其他警示性陳述或因素的限制,無法保證實際業績或發展會實現,即使已基本實現,也無法保證它們會對公司產生預期的後果或影響。這些前瞻性陳述自本新聞稿發佈之日起作出,除非法律要求,否則公司沒有義務更新或修改這些陳述以反映後續信息、事件或情況或其他方面。加拿大證券交易所尚未審查或批准本新聞稿的內容。
Non-IFRS Financial Measures
非國際財務報告準則財務指標
This press release includes references to "Adjusted EBITDA", which are not defined under International Financial Reporting Standards (IFRS). The intent of these non-IFRS measures is to provide additional useful information to investors and analysts. These non-IFRS measures do not have a standardized meaning prescribed by IFRS and is therefore unlikely to be comparable to similar measures presented by other entities. As such, these non-IFRS measures should not be considered in isolation or used as a substitute for measures of performance prepared in accordance with IFRS.
本新聞稿提及 “調整後的息稅折舊攤銷前利潤”,國際財務報告準則(IFRS)未對此進行定義。這些非國際財務報告準則指標的目的是爲投資者和分析師提供更多有用的信息。這些非國際財務報告準則指標不具有《國際財務報告準則》規定的標準化含義,因此不太可能與其他實體提出的類似指標相提並論。因此,不應孤立地考慮這些非《國際財務報告準則》指標,也不應將其用作根據《國際財務報告準則》編制的業績衡量標準的替代品。
Adjusted EBITDA is calculated as EBITDA plus share based compensation expense. Adjusted EBITDA is considered as a useful measure by management to understand the profitability of Nextleaf Solutions excluding the effects of certain non-operating items.
調整後的息稅折舊攤銷前利潤按息稅折舊攤銷前利潤加上基於股份的薪酬支出計算。管理層認爲調整後的息稅折舊攤銷前利潤是了解Nextleaf Solutions盈利能力的有用衡量標準,不包括某些非經營項目的影響。
[1] Non-IFRS or supplementary financial measure. See discussion in the Non-IFRS Financial Measures advisories section of this press release.
[1] 非國際財務報告準則或補充財務指標。請參閱本新聞稿非國際財務報告準則財務指標諮詢部分的討論。
[2] Non-IFRS or supplementary financial measure. See discussion in the Non-IFRS Financial Measures advisories section of this press release.
[2] 非國際財務報告準則或補充財務指標。請參閱本新聞稿非國際財務報告準則財務指標諮詢部分的討論。
[3] Non-IFRS or supplementary financial measure. See discussion in the Non-IFRS Financial Measures advisories section of this press release.
[3] 非國際財務報告準則或補充財務指標。請參閱本新聞稿非國際財務報告準則財務指標諮詢部分的討論。